@Article{096504017X14900505020895,
AUTHOR = {Hua Tao, Pudong Qian, Feijiang Wang, Hongliang Yu, Yesong Guo},
TITLE = {Targeting CD47 Enhances the Efficacy of Anti-PD-1 and CTLA-4 in an Esophageal Squamous Cell Cancer Preclinical Model},
JOURNAL = {Oncology Research},
VOLUME = {25},
YEAR = {2017},
NUMBER = {9},
PAGES = {1579--1587},
URL = {http://www.techscience.com/or/v25n9/56942},
ISSN = {1555-3906},
ABSTRACT = {Esophageal squamous cell cancer is a highly aggressive cancer with a dismal 5-year survival rate. CD47 is a
cell transmembrane protein that is involved in cell apoptosis, proliferation, adhesion, migration, and antigen
presentation in the immune system. By interacting with signal regulatory protein-a expressed in antigenpresenting cells (APCs), CD47 acts as an antiphagocytic mechanism to inhibit APC-dependent antigen presentation. Overexpression of CD47 was found in various types of cancer. However, its role in esophageal
squamous cell cancer is not yet clear. Anti-CD47 is an antagonist of CD47 signaling pathways by competing with its ligand. In the current study, we investigated the effects of anti-CD47 treatment on the antitumor
immune response in an esophageal squamous cell cancer preclinical model. We found that anti-CD47 treatment enhanced proinflammatory responses and increased CD8+
T-cell infiltration in tumor tissue in the animal
model. T cells in anti-CD47-treated tumors showed higher PD-1 and CTLA-4 expression, indicating T-cell
activation and the rationale of combining anti-CD47 with anti-PD-1 and CLTA-4. The combinatory treatment
showed the best antitumor response, implying a novel treatment strategy. The effects of anti-CD47 depended
on dendritic cell function. In patient samples, expression of CD47 was negatively correlated with CD8+
T-cell
infiltration in esophageal squamous cell cancer patients. Taken together, CD47 might be a novel target to
enhance anti-PD-1 and CLTA-4 efficacy in esophageal squamous cell cancer.},
DOI = {10.3727/096504017X14900505020895}
}